Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 9/20 | 0.38 |
| ▸ | SUV39H2 | Q9H5I1 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | STK17B | O94768 | 1/20 | 0.36 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4872156 | 0.87 | NQO2 (0.39) | NQO2BRD4HTTNPSR1STK17B | |
| SCHEMBL14107491 | 0.80 | CCR2 (0.42) | — | |
| SCHEMBL31600640 | 0.73 | LMNA (0.41) | NQO2BRD4HTTNPSR1STK17B | |
| SCHEMBL31528049 | 0.71 | NQO2 (0.42) | NQO2HTTNPSR1STK17BSTK17A | |
| SCHEMBL21633558 | 0.71 | NQO2 (0.42) | NQO2HTTNPSR1STK17BSTK17A | |
| SCHEMBL18072436 | 0.70 | CACNA1H (0.44) | BRD4NPSR1TDP1CACNA1HCACNA1B | |
| SCHEMBL31349507 | 0.70 | CACNA1H (0.44) | BRD4CACNA1HCACNA1BCACNA1CALDH1A1 | |
| SCHEMBL22790866 | 0.69 | NQO2 (0.48) | NQO2HTTNPSR1STK17BSTK17A | |
| SCHEMBL18072434 | 0.69 | CACNA1H (0.45) | CACNA1HCACNA1BCACNA1CTRPV1 | |
| SCHEMBL31414671 | 0.68 | NQO2 (0.43) | NQO2BRD4SUV39H2HTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388019-B2 | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060074087-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074087-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | NQO2 1375/4885BRD4 1446/4885SUV39H2 3212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.